NYSE:OGNPharmaceuticals
Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials
Organon (OGN) is back on investors radar after releasing detailed sub analysis data from its Phase 3 ADORING trials, which showed that VTAMA cream improved sleep outcomes in children with atopic dermatitis and their families.
See our latest analysis for Organon.
Despite the encouraging VTAMA data, Organon’s recent share price performance has been weak, with a 30 day share price return of negative 18.0% and a 1 year total shareholder return decline of 50.6%, suggesting sentiment remains...